Showing results (51-60 of 125) with videos related to
Sort By:
Pageof 13
Plos One|June 9, 2017
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomicsAngelo Gámez-Pozo, Lucía Trilla-Fuertes, Guillermo Prado-Vázquez, et al.Breast Cancer Research and Treatment|September 3, 2020
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)Santiago González-Santiago, Cristina Saura, Eva Ciruelos, et al.Cancer Research|April 18, 2015
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical ImplicationsAngelo Gámez-Pozo, Julia Berges-Soria, Jorge M Arevalillo, et al.Breast Cancer Research and Treatment|July 14, 2026
Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitorsSantiago Terán, María Illia, María Carla Quevedo, et al.The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.The Lancet. Oncology|October 3, 2014
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trialGunter von Minckwitz, Fabio Puglisi, Javier Cortes, et al.NPJ Breast Cancer|November 26, 2024
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapySonia Pernas, Esther Sanfeliu, Guillermo Villacampa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerHope S Rugo, Aditya Bardia, Frederik Marmé, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJosé Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.Frontiers in Oncology|July 26, 2021
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE StudyMiguel J Gil-Gil, Meritxell Bellet, Milana Bergamino, et al.Pageof 13